H-1B sponsorship profile: Stemline Therapeutics, Inc. Across U.S. Department of Labor LCA disclosures, Stemline Therapeutics, Inc filed 10 Labor Condition Applications covering 10 H-1B worker positions between fiscal year 2023 and fiscal year 2025. The employer’s DOL certification rate sits at 90% (9 certified of 10 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Stemline Therapeutics, Inc’s H-1B petitions range from $118,052 at the low end to $326,000 at the high end, with a petition-weighted average of $223,298. That range reflects the mix of occupations the company sponsors, led by AVP, Commercial Excellence Analytics (4 petitions at $318,000 avg), followed by Sr. Manager, R&D and Associate Director, Data Strategy & Omnichannel Enablement. H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Stemline Therapeutics, Inc is headquartered in New York, NY under NAICS code 54171, and places H-1B workers across 2 states, most heavily in NY, NJ. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Stemline Therapeutics, Inc ranks. By H-1B petition volume, Stemline Therapeutics, Inc is #16,610 of 119,880 employers nationally and #1,422 of 14,719 employers headquartered in NY. Both ranks are computed live from the same underlying petition counts, not a separate estimate.